Literature DB >> 34235557

Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Tomohiko Tanigawa1, Masatoshi Sakurai2, Jun Kato1, Kota Mizuno1, Shinya Fujita1, Yuya Koda1, Taku Kikuchi1, Takayuki Shimizu1, Shinichiro Okamoto1, Keisuke Kataoka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34235557     DOI： 10.1007/s00277-021-04586-w

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  9 in total

1.  Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.

Authors:  Mauricette Michallet; Peter Dreger; Mohamad Sobh; Linda Koster; Jennifer Hoek; Ariane Boumendil; Christof Scheid; Christopher P Fox; Gerald Wulf; William Krüger; Michel van Gelder; Paolo Corradini; Domenico Russo; Jakob Passweg; Hélène Schoemans; Wolfgang Bethge; Nicolaas Schaap; Jan Cornelissen; Paul Browne; Nadira Durakovic; Lutz Muller; Silvia Montoto; Nicolaus Kroger; Johannes Schetelig
Journal:  Bone Marrow Transplant       Date:  2019-11-07       Impact factor: 5.483

2.  Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.

Authors:  Anne Wanquet; Rudy Birsen; Richard Lemal; Mathilde Hunault; Véronique Leblond; Thérèse Aurran-Schleinitz
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

3.  Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.

Authors:  Constantine S Tam; Thomas Kimber; John F Seymour
Journal:  Br J Haematol       Date:  2016-02-25       Impact factor: 6.998

4.  Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Idanna Innocenti; Federica Sora; Francesco Autore; Patrizia Chiusolo; Sabrina Giammarco; Elisabetta Metafuni; Andrea Bacigalupo; Simona Sica; Luca Laurenti
Journal:  Hematol Oncol       Date:  2020-11-20       Impact factor: 5.271

5.  Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Authors:  Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

6.  Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Sima Jeha; Carlos E Bueso-Ramos; Sherry Pierce; Jianqin Shan; Charles Koller; Miloslav Beran; Michael Keating; Emil J Freireich
Journal:  Cancer       Date:  2004-12-15       Impact factor: 6.860

7.  A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

Authors:  R A Larson; R K Dodge; C A Linker; R M Stone; B L Powell; E J Lee; P Schulman; F R Davey; S R Frankel; C D Bloomfield; S L George; C A Schiffer
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

Review 8.  Central nervous system localisation of chronic lymphocytic leukaemia, description of two very distinct cases and a review of the literature.

Authors:  Nyanza K L M Timmers; Josanne S de Maar; Rob C M van Kruijsdijk; Saskia K Klein
Journal:  Ann Hematol       Date:  2018-04-29       Impact factor: 3.673

9.  Refractory Chronic Lymphocytic Leukemia with Central Nervous System Involvement: A Case Report with Literature Review.

Authors:  Takahisa Nakanishi; Tomoki Ito; Shinya Fujita; Atsushi Satake; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Shosaku Nomura
Journal:  J Blood Med       Date:  2020-12-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.